About: Dianicline

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Dianicline (SSR-591,813) is a drug developed by Sanofi-Aventis which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It is being developed as a medication for the treatment of nicotine dependence to assist in smoking cessation. Dianicline is very similar to the already marketed drug varenicline and it is unclear what advantages it will have over the older drug, although it may have an improved side effect profile. It has been through human trials up to Phase II, although results have not yet been reported. Drug development has been discontinued after reporting of unfavourable results during Phase III trials.

Property	Value
dbo:abstract	Dianicline (SSR-591,813) is a drug developed by Sanofi-Aventis which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It is being developed as a medication for the treatment of nicotine dependence to assist in smoking cessation. Dianicline is very similar to the already marketed drug varenicline and it is unclear what advantages it will have over the older drug, although it may have an improved side effect profile. It has been through human trials up to Phase II, although results have not yet been reported. Drug development has been discontinued after reporting of unfavourable results during Phase III trials. (en)
dbo:casNumber	292634-27-6
dbo:chEMBL	187927
dbo:fdaUniiCode	Y0SNM34C6O
dbo:pubchem	9816447
dbo:thumbnail	wiki-commons:Special:FilePath/Dianicline_structure.svg?width=300
dbo:wikiPageID	17713911 (xsd:integer)
dbo:wikiPageLength	3601 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1084615965 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Partial_agonist dbc:Bridged_heterocyclic_compounds dbr:Varenicline dbr:Smoking_cessation dbc:Stimulants dbr:Alpha-4_beta-2_nicotinic_receptor dbr:Nicotine dbc:Nicotinic_agonists dbc:Pyridines dbc:Azepines dbr:Nicotinic_acetylcholine_receptor dbr:Sanofi-Aventis
dbp:atcPrefix	none (en)
dbp:c	13 (xsd:integer)
dbp:casNumber	292634 (xsd:integer)
dbp:chembl	187927 (xsd:integer)
dbp:chemspiderid	8352269 (xsd:integer)
dbp:h	16 (xsd:integer)
dbp:image	Dianicline-3D-balls.png (en)
dbp:iupacName	120.0
dbp:molecularWeight	216.278000 (xsd:double)
dbp:n	2 (xsd:integer)
dbp:o	1 (xsd:integer)
dbp:pubchem	9816447 (xsd:integer)
dbp:smiles	C1CN2CC[C@@]3[C@H]1OC4=CN=CC=C4 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	SUPRUPHAEXPGPF-QWHCGFSZSA-N (en)
dbp:unii	Y0SNM34C6O (en)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	444161407 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Reflist dbt:Short_description dbt:Stimulants dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Stdinchicite dbt:Nicotinic_acetylcholine_receptor_modulators dbt:Drugs_used_in_addictive_disorders
dcterms:subject	dbc:Bridged_heterocyclic_compounds dbc:Stimulants dbc:Nicotinic_agonists dbc:Pyridines dbc:Azepines
gold:hypernym	dbr:Drug
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatStimulants yago:Abstraction100002137 yago:Base114618253 yago:Chemical114806838 yago:Cognition100023271 yago:Compound114818238 yago:Information105816287 yago:Material114580897 yago:Matter100020827 yago:Part113809207 yago:PhysicalEntity100001930 yago:PsychologicalFeature100023100 yago:Pyridine114692510 yago:Relation100031921 dbo:Drug yago:Stimulation105827684 yago:Substance100019613 yago:WikicatPyridines umbel-rc:DrugProduct
rdfs:comment	Dianicline (SSR-591,813) is a drug developed by Sanofi-Aventis which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It is being developed as a medication for the treatment of nicotine dependence to assist in smoking cessation. Dianicline is very similar to the already marketed drug varenicline and it is unclear what advantages it will have over the older drug, although it may have an improved side effect profile. It has been through human trials up to Phase II, although results have not yet been reported. Drug development has been discontinued after reporting of unfavourable results during Phase III trials. (en)
rdfs:label	Dianicline (en)
owl:sameAs	freebase:Dianicline yago-res:Dianicline wikidata:Dianicline dbpedia-sh:Dianicline dbpedia-sr:Dianicline https://global.dbpedia.org/id/4j4Ag
prov:wasDerivedFrom	wikipedia-en:Dianicline?oldid=1084615965&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Dianicline-3D-balls.png wiki-commons:Special:FilePath/Dianicline_structure.svg
foaf:isPrimaryTopicOf	wikipedia-en:Dianicline
is dbo:wikiPageWikiLink of	dbr:C13H16N2O dbr:Alpha-4_beta-2_nicotinic_receptor dbr:List_of_drugs:_Df–Di
is foaf:primaryTopic of	wikipedia-en:Dianicline